SAN DIEGO, June 9 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN)
today announced that William G. Gerber, M.D. and Frank H. Jellinek, Jr. have
joined its board of directors following their election at the annual meeting
of shareholders. It also announced that Val Buonaiuto has retired following
over five years as a Nanogen director. All shareholder proposals were
approved today at the 2005 annual meeting held in San Diego.
Dr. Gerber is a partner at Bay City Capital, a life sciences investment
fund, and is chairman of the board of directors of Pathway Diagnostics. He
was most recently president and chief executive officer of Epoch BioSciences
until its merger with Nanogen in December, 2004. Dr. Gerber has held various
officer-level positions at diaDexus LLC, Onyx Pharmaceuticals and Chiron
Diagnostics during his broad scientific and commercial career.
Mr. Jellinek is currently chairman emeritus of Fisher Scientific
International and was formerly the president, chief executive officer and a
director of Apogent Technologies Inc. until it was acquired by Fisher in 2004.
He was previously the president and chief executive officer of Apogent's
subsidiary, Sybron Laboratory Products Corporation, and served as president of
Apogent's Erie Scientific Company subsidiary for sixteen years.
"I am very pleased to add the broad industry experience that Bill and
Frank bring to the Nanogen board of directors," said Howard C. Birndorf,
Nanogen's chairman of the board and CEO. "Frank's extensive merger and
acquisition background together with Bill's medical and diagnostics expertise
will nicely complement the capabilities and experience of our other board
members. All of us at Nanogen are appreciative of the contributions made by
Val during his several years of service to Nanogen, and we wish him continued
About Nanogen, Inc.
Nanogen's advanced diagnostics provide researchers, clinicians, physicians
and patients worldwide with improved methods and tests that can predict,
diagnose and ultimately help treat disease. Nanogen's products include real-
time PCR reagents, the NanoChip(R) Molecular Biology Workstation platform for
molecular diagnostic applications and the Nexus Dx(TM) line of point-of-care
diagnostic tests for cardiac related health conditions. Nanogen's ten years
of pioneering research involving nanotechnology may also have future
applications in medical diagnostics, biowarfare and other industries. For
additional information please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether products under development can be successfully
developed and commercialized, whether results reported by our customers or
partners can be identically replicated, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.